FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
On 15 April 2025, the European Medicines Regulatory Network rolled out an interactive trial map—empowering patients and professionals …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
Prime Minister Starmer unveils ambitious reforms to speed up trial timelines and centralize NHS data, aiming to restore …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
Australia’s National Genomic Registry is connecting patients, clinicians, and researchers to transform rare disease care in real time.
Already a subscriber? Log in